CagriSema + Semaglutide for Obesity

This trial tests a new treatment called CagriSema to evaluate its effectiveness in helping people with obesity, with or without type 2 diabetes, lose weight. Participants will receive either CagriSema or semaglutide, a drug already used for weight management, to compare their effects. The main goal is to assess the safety and effectiveness of CagriSema for weight loss over approximately 83 weeks. This trial may suit individuals with a BMI of 35 or higher who have not recently used certain weight-loss medications. As a Phase 3 trial, it represents the final step before FDA approval, allowing participants to contribute to the development of a potentially groundbreaking treatment.

The trial requires that you have not used any medications with GLP-1 RA activity or amylin analogues in the 6 months before screening. If you are taking these types of medications, you would need to stop them to participate.

Research has shown that CagriSema is generally safe, with side effects similar to other common treatments. Some studies found that it can lead to significant weight loss and causes less vomiting compared to other options. Semaglutide, already a prescribed medication, has a strong safety record. It has proven effective in aiding weight loss and is considered safe in clinical trials.

Researchers are excited about these treatments, CagriSema and Semaglutide, because they offer innovative approaches to tackling obesity. Unlike standard treatments like lifestyle changes and medications such as orlistat, Semaglutide has already gained attention for its ability to effectively manage weight by mimicking a hormone that controls appetite. CagriSema is especially intriguing because it combines Semaglutide with another component, potentially enhancing its effectiveness. This combination might offer more significant weight loss than current options, providing a promising new avenue for individuals struggling with obesity.

This trial will compare the effects of CagriSema and Semaglutide for obesity. Studies have shown that CagriSema can lead to significant weight loss. In one study, participants lost up to 22.7% of their body weight with this treatment, while those with type 2 diabetes lost about 15.7%. Semaglutide, a medication already available for prescription, also demonstrates strong results, with an average weight loss of 14.9%. Both treatments show promise in helping individuals with obesity, regardless of type 2 diabetes status, to lose weight. Participants in this trial will receive either CagriSema at different dose levels or Semaglutide to evaluate their effectiveness.²³⁶⁷⁸